{"id":26396,"date":"2022-10-27T09:00:00","date_gmt":"2022-10-27T09:00:00","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/press-releases\/ipsen-enregistre-une-forte-croissance-des-ventes-au-cours-des-neuf-premiers-mois-de-2022-et-confirme-ses-objectifs-financiers-pour-2022\/"},"modified":"2023-05-26T11:58:10","modified_gmt":"2023-05-26T11:58:10","slug":"ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance","status":"publish","type":"press_release","link":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/","title":{"rendered":"Ipsen enregistre une forte croissance des ventes au cours des neuf premiers mois de 2022 et confirme ses objectifs financiers pour 2022"},"content":{"rendered":"\n<p><strong>Paris (France), le 27 octobre 2022<\/strong><\/p>\n\n\n\n<p>Ipsen (Euronext: IPN&nbsp;; ADR&nbsp;: IPSEY), groupe biopharmaceutique mondial de sp\u00e9cialit\u00e9, pr\u00e9sente aujourd\u2019hui son chiffre d\u2019affaires r\u00e9alis\u00e9 depuis le d\u00e9but de l\u2019exercice et pour le troisi\u00e8me trimestre 2022.<\/p>\n\n\n\n<p><strong>Synth\u00e8se des ventes<\/strong><sup><strong>1<\/strong><\/sup><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td rowspan=\"2\">&nbsp;<\/td><td>&nbsp;<\/td><td><strong>9 mois<br>2022<\/strong><\/td><td><strong>9 mois<br>2021<\/strong><\/td><td colspan=\"2\"><strong>% variation<\/strong><\/td><td>&nbsp;<\/td><td><strong>T3<\/strong><br><strong>2022<\/strong><\/td><td><strong>T3<\/strong><br><strong>2021<\/strong><\/td><td colspan=\"2\"><strong>% variation<\/strong><\/td><\/tr><tr><td>&nbsp;<\/td><td><strong>m\u20ac<\/strong><\/td><td><strong>m\u20ac<\/strong><\/td><td><strong>Publi\u00e9<\/strong><\/td><td><strong>TCC<\/strong><sup><strong>2<\/strong><\/sup><\/td><td>&nbsp;<\/td><td><strong>\u20acm<\/strong><\/td><td><strong>\u20acm<\/strong><\/td><td><strong>Publi\u00e9<\/strong><\/td><td><strong>TCC<\/strong><sup><strong>2<\/strong><\/sup><\/td><\/tr><tr><td>Oncologie<\/td><td>&nbsp;<\/td><td>1&nbsp;767,2<\/td><td>1 565,4<\/td><td>12,9%<\/td><td>6,9%<\/td><td>&nbsp;<\/td><td>603,1<\/td><td>552,3<\/td><td>9,2%<\/td><td>1,2%<\/td><\/tr><tr><td>Neurosciences<\/td><td>&nbsp;<\/td><td>407,7<\/td><td>309,6<\/td><td>31,7%<\/td><td>25,1%<\/td><td>&nbsp;<\/td><td>160,7<\/td><td>103,8<\/td><td>54,8%<\/td><td>43,4%<\/td><\/tr><tr><td>Maladies Rares<\/td><td>&nbsp;<\/td><td>33,6<\/td><td>37,3<\/td><td>-9,8%<\/td><td>-12,5%<\/td><td>&nbsp;<\/td><td>11,0<\/td><td>11,7<\/td><td>-5,4%<\/td><td>-9,3%<\/td><\/tr><tr><td><strong>Chiffre d\u2019affaires Groupe<\/strong><\/td><td>&nbsp;<\/td><td><strong>2 208,5<\/strong><\/td><td><strong>1 912,3<\/strong><\/td><td><strong>15,5%<\/strong><\/td><td><strong>9,5%<\/strong><\/td><td>&nbsp;<\/td><td><strong>774,8<\/strong><\/td><td><strong>667,8<\/strong><\/td><td><strong>16,0%<\/strong><\/td><td><strong>7,6%<\/strong><\/td><\/tr><tr><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><td>&nbsp;<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Faits marquants<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\" type=\"disc\">\n<li>Croissance des ventes totales de 9,5% \u00e0 taux de change constant<sup>2<\/sup>, ou de 15,5% en donn\u00e9es publi\u00e9es, tir\u00e9e par les plateformes de croissance avec Dysport<sup>\u00ae<\/sup>&nbsp;(<em>toxine botulique de type&nbsp;A)<\/em>, D\u00e9capeptyl<sup>\u00ae<\/sup>&nbsp;(<em>triptor\u00e9line<\/em>), Cabometyx<sup>\u00ae<\/sup>&nbsp;(<em>cabozantinib<\/em>) et Onivyde<sup>\u00ae<\/sup>&nbsp;<em>(irinot\u00e9can)<\/em>&nbsp;en hausse de 20,8%&nbsp;; les ventes de Somatuline<sup>\u00ae<\/sup>&nbsp;(<em>lanr\u00e9otide<\/em>) sont en baisse de 2,8%<sup>2<\/sup><\/li>\n\n\n\n<li>Au troisi\u00e8me trimestre, croissance des ventes totales de 7,6% \u00e0 taux de change constant2, ou de 16,0% en donn\u00e9es publi\u00e9es, port\u00e9e par la croissance des ventes de Dysport de 43,3%<sup>2<\/sup>, partiellement impact\u00e9e par la baisse des ventes de Somatuline de 9,8%<sup>2<\/sup><\/li>\n\n\n\n<li>Finalisation de l\u2019acquisition d\u2019Epizyme, \u00e9largissant la pr\u00e9sence d\u2019Ipsen en Oncologie<strong>&nbsp;<\/strong><\/li>\n\n\n\n<li>Report de la r\u00e9union pr\u00e9vue du Comit\u00e9 consultatif des autorit\u00e9s r\u00e9glementaires am\u00e9ricaines (FDA) concernant le m\u00e9dicament exp\u00e9rimental palovarot\u00e8ne<strong>&nbsp;<\/strong><\/li>\n\n\n\n<li>Objectifs financiers annuels confirm\u00e9s pour 2022 avec une croissance des ventes totales sup\u00e9rieure \u00e0 7,0% \u00e0 taux de change constant<sup>2<\/sup>&nbsp;et une marge op\u00e9rationnelle des activit\u00e9s sup\u00e9rieure \u00e0 36,0% des ventes totales du Groupe<\/li>\n<\/ul>\n\n\n\n<p><strong>David Loew, Directeur g\u00e9n\u00e9ral d\u2019Ipsen, a d\u00e9clar\u00e9 :<\/strong><\/p>\n\n\n\n<p>\u00ab<em>&nbsp;Je suis fier de la performance d\u2019Ipsen depuis le d\u00e9but de l\u2019ann\u00e9e alors que nous continuons de d\u00e9livrer de solides performances commerciales.<\/em>&nbsp;<em>Nos plateformes de croissance ont enregistr\u00e9 une progression des ventes \u00e0 deux chiffres, refl\u00e9tant l\u2019am\u00e9lioration de notre ex\u00e9cution commerciale et la solidit\u00e9 de notre portefeuille.<\/em>&nbsp;<em>Ces r\u00e9sultats ont compens\u00e9 l\u2019impact n\u00e9gatif croissant de la concurrence pour Somatuline aux \u00c9tats-Unis et en Europe.<\/em>&nbsp;<em>Sur la base de la forte dynamique de nos ventes, nous confirmons nos objectifs financiers pour l\u2019ensemble de l\u2019ann\u00e9e.<\/em><\/p>\n\n\n\n<p><em>Je me r\u00e9jouis \u00e9galement du renforcement de notre portefeuille en R&amp;D, de nos produits commercialis\u00e9s et de notre organisation \u00e0 la suite \u00e0 l\u2019acquisition d\u2019Epizyme. A court terme, j\u2019attends avec impatience plusieurs \u00e9tapes de d\u00e9veloppement de notre portefeuille de produits en R&amp;D, notamment avec les donn\u00e9es de Phase III de plusieurs programmes en oncologie.<\/em>&nbsp;<em>Je suis satisfait des progr\u00e8s r\u00e9alis\u00e9s tandis que nous continuons \u00e0 maximiser la valeur de nos marques, \u00e0 renforcer notre portefeuille de produits en R&amp;D, \u00e0 g\u00e9n\u00e9rer des gains d\u2019efficacit\u00e9 et \u00e0 nous focaliser sur notre culture.&nbsp;<\/em>\u00bb<\/p>\n\n\n\n<p><strong>Objectifs financiers pour l\u2019ann\u00e9e 2022<\/strong><\/p>\n\n\n\n<p>Ipsen a confirm\u00e9 ses objectifs financiers pour l\u2019exercice 2022<sup>3<\/sup>&nbsp;:<\/p>\n\n\n\n<ul class=\"wp-block-list\" type=\"disc\">\n<li>Croissance des ventes totales du Groupe sup\u00e9rieure \u00e0 7,0%, \u00e0 taux de change constant. Sur la base des taux de change moyens en septembre 2022, Ipsen anticipe un impact additionnel favorable des devises de l\u2019ordre de 6% sur les ventes totales du Groupe.<\/li>\n\n\n\n<li>Marge op\u00e9rationnelle des activit\u00e9s sup\u00e9rieure \u00e0 36,0% des ventes totales du Groupe.<\/li>\n<\/ul>\n\n\n\n<p><strong>Business D\u00e9veloppement<\/strong><\/p>\n\n\n\n<p>En ao\u00fbt 2022, Ipsen et Epizyme, Inc. (Epizyme) ont annonc\u00e9 avoir finalis\u00e9 un accord de fusion d\u00e9finitif selon lequel Ipsen a acquis Epizyme, une soci\u00e9t\u00e9 biopharmaceutique int\u00e9gr\u00e9e depuis la recherche jusqu\u2019\u00e0 la commercialisation, engag\u00e9e \u00e0 d\u00e9velopper et fournir des traitements innovants gr\u00e2ce \u00e0 de nouveaux m\u00e9dicaments \u00e9pig\u00e9n\u00e9tiques pour les patients atteints de cancer. Les ventes par Ipsen de Tazverik<sup>\u00ae<\/sup>&nbsp;(<em>tazemetostat<\/em>), \u00e0 partir du 1er septembre 2022, sont incluses dans les chiffres du troisi\u00e8me trimestre.<\/p>\n\n\n\n<p>Ipsen et Marengo Therapeutics, Inc. (Marengo) ont annonc\u00e9 en ao\u00fbt 2022 la conclusion d\u2019un partenariat strat\u00e9gique afin de d\u00e9velopper en phase clinique deux traitements candidats pr\u00e9cliniques \u00e0 partir de la plateforme STAR de Marengo. Cette collaboration b\u00e9n\u00e9ficiera non seulement de l\u2019expertise unique de Marengo en R&amp;D concernant un nouveau m\u00e9canisme d\u2019activation des lymphocytes T, mais aussi de la pr\u00e9sence internationale d\u2019Ipsen en oncologie dans le cadre du d\u00e9veloppement clinique et de la commercialisation.<\/p>\n\n\n\n<p><strong>Palovarot\u00e8ne<\/strong><\/p>\n\n\n\n<p>En octobre 2022, les autorit\u00e9s r\u00e9glementaires am\u00e9ricaines (FDA) ont annonc\u00e9 leur d\u00e9cision de reporter la r\u00e9union pr\u00e9vue du Comit\u00e9 consultatif sur les traitements des maladies endocriniennes et m\u00e9taboliques concernant le m\u00e9dicament exp\u00e9rimental palovarot\u00e8ne. La nouvelle date sera confirm\u00e9e prochainement. La r\u00e9union du Comit\u00e9 consultatif \u00e9tait initialement pr\u00e9vue le 31 octobre 2022. La FDA a inform\u00e9 Ipsen que le report est li\u00e9 \u00e0 une nouvelle demande d\u2019informations de sa part sur les donn\u00e9es des essais cliniques sur le palovarot\u00e8ne, et ne concerne aucunement le profil de s\u00e9curit\u00e9 du m\u00e9dicament. Ipsen s\u2019emploie actuellement \u00e0 traiter cette demande.<\/p>\n\n\n\n<p><strong>Conf\u00e9rence t\u00e9l\u00e9phonique (en anglais)<\/strong><\/p>\n\n\n\n<p>Une conf\u00e9rence t\u00e9l\u00e9phonique et un webcast destin\u00e9s aux investisseurs et analystes se tiendront aujourd\u2019hui \u00e0 13h30, heure de Paris. Les participants peuvent s\u2019inscrire \u00e0 la conf\u00e9rence via ce&nbsp;<a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=LWKMROiD4fJjvdL7i6Krjr3ak8-4QRBPw8wJDqMr1_TVl79ObgVgNFCZspju5FxdDfwNa6sc5KsfyFwcR-D-k5Wjyf_r9uPkYhjeIChGrXEK_hTqqD4rJ-HKOpNzO2wQCWHarJ6RMhmOf10UHHwOqAD3Skzk8y-LP4CiJGlyE0SJUTgut0Kmxm7gvYY1mSU7uMTp51Gz4OIi4lkPCNA2qoxW8AD0FIlj9cWBDg31lsyJMrrHcs1j3MtmQwrQdki3vCB7YQf3qMixoRc0nifMYSb7yXPsGm2UfIhYKU8l2sIyrLagm18G5Kw2UrtBSWxdSPC0UXLAOd9BQmPLOV89tHhP4J-QpOD_-2EA_McGgyoyqLxmEA4f1FKP9tCIJzEL86NS6-5jBZm2OLRMMO-9AyDLyg1Zg2_Lp7GbftI707rk44W2nO-Sk4zNZ2ikXAAjZgwPetznONKgRNFlMlk9HSFPF1q0Pg62XOzz40z06vFNDuBgSHS9XlhRtk7k9XU1b-tFpr3LtC-qXpOlEwbTmYMZDDNcGYwaM5zZEziPbWZGDVYNVwdz7JGe3AM2v7Eboq8uj8wN1HeABDmK8hiCh8Jan0zchiFn9Rra_qKAcOd3YekkCPz8dngZfWjjAnTP4wxdpNcYwj_RH-5MVC8Zww==\" target=\"_blank\" rel=\"nofollow noopener\"><strong><u>lien<\/u><\/strong><\/a>; les informations sur le webcast sont disponibles&nbsp;<a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=XoB9drRUD8fkms0uRJ7l0i3xGevqq6POScBgnJ0n7jBNp37JQxOqIHJ_JNdGdo6WrcFG-vSAj5Yczb4qCXtITScFCYF53bIbJTAPkqcmTrKAAHPtEGCKmvA0NCSFormZ\" target=\"_blank\" rel=\"nofollow noopener\"><strong><u>ici<\/u><\/strong><\/a>. Un enregistrement sera disponible sur le site Web&nbsp;<a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=0gwkEgWCtGhZekaJ9guqmhs36J6HWmaWmadOPrSf7CzNtzER0pF2JCWeEj8iwwEH1_HxpciKSfvIPOteIBVRXg==\" target=\"_blank\" rel=\"nofollow noopener\"><strong><u>ipsen.com<\/u><\/strong><\/a>.<\/p>\n\n\n\n<p><strong>Calendrier<\/strong><\/p>\n\n\n\n<p>Ipsen pr\u00e9voit de publier ses r\u00e9sultats annuels le 9 f\u00e9vrier 2023.<\/p>\n\n\n\n<p><strong>Notes<\/strong><\/p>\n\n\n\n<p>Tous les chiffres financiers sont exprim\u00e9s en millions d\u2019euros (m\u20ac). Sauf indication contraire, les performances publi\u00e9es dans le pr\u00e9sent communiqu\u00e9 couvrent la p\u00e9riode de neuf mois courant jusqu\u2019au 30 septembre 2022 (depuis le d\u00e9but de l\u2019exercice, les neuf premiers mois de 2022) et la p\u00e9riode de trois mois jusqu\u2019au 30 septembre 2022 (le troisi\u00e8me trimestre ou T3 2022), comparativement \u00e0 la p\u00e9riode de neuf mois jusqu\u2019au 30 septembre 2021 (les neuf premiers mois de 2021) et la p\u00e9riode de trois mois jusqu\u2019au 30 septembre 2021 (T3 2021) respectivement. Sauf indication contraire, les commentaires sont bas\u00e9s sur les performances r\u00e9alis\u00e9es depuis le d\u00e9but de l\u2019exercice, soit les neuf premiers mois de 2022. La performance de l\u2019activit\u00e9 en Sant\u00e9 Familiale, c\u00e9d\u00e9e en juillet 2022, a \u00e9t\u00e9 exclue de tous les commentaires et comparaisons avec la performance ant\u00e9rieure.<strong>&nbsp;<\/strong><\/p>\n\n\n\n<p><strong>Ipsen<\/strong><\/p>\n\n\n\n<p>Ipsen est un groupe biopharmaceutique de taille moyenne leader au niveau mondial, focalis\u00e9 sur la mise au point de m\u00e9dicaments innovants en Oncologie, Maladies Rares et Neurosciences. Avec un chiffre d\u2019affaires de 2,6 milliards d\u2019euros en M\u00e9decine de Sp\u00e9cialit\u00e9 au cours de l\u2019exercice 2021, Ipsen vend des m\u00e9dicaments dans plus de 100 pays. Parall\u00e8lement \u00e0 sa strat\u00e9gie d\u2019innovation externe, la R&amp;D d\u2019Ipsen est focalis\u00e9e sur ses plateformes technologiques diff\u00e9renci\u00e9es et innovantes situ\u00e9es au c\u0153ur des clusters mondiaux de la recherche biotechnologique ou en sciences de la vie : Paris-Saclay, France ; Oxford, Royaume-Uni ; Cambridge, Etats-Unis ; Shanghai, Chine. Ipsen emploie environ 5 000 collaborateurs dans le monde. Ipsen est cot\u00e9 \u00e0 Paris (Euronext: IPN) et aux \u00c9tats-Unis \u00e0 travers un programme d\u2019American Depositary Receipt (ADR : IPSEY) sponsoris\u00e9 de niveau I. Le site Internet d\u2019Ipsen est&nbsp;<a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=0gwkEgWCtGhZekaJ9guqmvmIxYMBBEe1sUWiAmgwPusHxtR_aKCD7GS0X0hgqQAdmbOk8BfrBRqbZZD5T2OM2Q==\" target=\"_blank\" rel=\"nofollow noopener\"><strong><u>ipsen.com<\/u><\/strong><\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Contacts<\/strong><\/td><td>&nbsp;<\/td><\/tr><tr><td><strong><u>Investisseurs<\/u><\/strong><\/td><td>&nbsp;<\/td><\/tr><tr><td><strong>Craig Marks<\/strong>\n<p>&nbsp;<\/p>\n<p>Vice-Pr\u00e9sident, Relations Investisseurs<\/p>\n<p>+44 (0)7584 349 193<\/p>\n<\/td><td><strong>Adrien Dupin de Saint-Cyr<\/strong>\n<p>&nbsp;<\/p>\n<p>Responsable des relations investisseurs<\/p>\n<p>+33 6 64 26 17 49<\/p>\n<\/td><\/tr><tr><td><strong><u>Media<\/u><\/strong><\/td><td>&nbsp;<\/td><\/tr><tr><td><strong>Amy Wolf<\/strong>\n<p>&nbsp;<\/p>\n<p>Vice-Pr\u00e9sident, strat\u00e9gie de la marque Corporate<\/p>\n<p>et de la communication<\/p>\n<p>+41 79 576 07 23<\/p>\n<\/td><td><strong>Ioana&nbsp;Piscociu<\/strong>\n<p>&nbsp;<\/p>\n<p>Responsable senior,<br>Relations Global Media<\/p>\n<p>+33 6 69 09 12 96<\/p>\n<\/td><\/tr><tr><td>&nbsp;<\/td><td>&nbsp;<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Chiffre d\u2019affaires consolid\u00e9 IFRS non audit\u00e9<\/li>\n\n\n\n<li>Variation \u00e0 taux de change constant, hors effets de change, \u00e9tabli en recalculant les performances de la p\u00e9riode consid\u00e9r\u00e9e sur la base des taux de change utilis\u00e9s pour la p\u00e9riode pr\u00e9c\u00e9dente.<\/li>\n\n\n\n<li>Excluant toute contribution de l\u2019activit\u00e9 en Sant\u00e9 Familiale, c\u00e9d\u00e9e en juillet 2022.<\/li>\n<\/ol>\n\n\n\n<p id=\"gnw_attachments_section-header\"><strong>Pi\u00e8ces jointes<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\" id=\"gnw_attachments_section-items\">\n<li><a title=\"Annonce-des-ventes-realisees-au-troisieme-trimestre-2022\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=YyXYY2oYga9YN9WU9tdXnQWz_jOm4VLdUqDXphjwPgKcnpMgKThymexdRPOdmBEBjt54MTErxrs6Pv2xKaNrU6ZpizlEatUUzx_Un6TVdoFNaapGn-d1bybIoNY1jbUXuEKDLByjtYuh_otQuvIQwbMWMz7jqawra7LphvXmlJ61Bon9BrIia6SG847jr2hTQ9Dx6FqmnJNDJsiuEbG2XuDfiJb-kclLZCtWW_xpg60=\" target=\"_blank\" rel=\"nofollow noopener\">Annonce-des-ventes-realisees-au-troisieme-trimestre-2022<\/a><\/li>\n\n\n\n<li><a title=\"YTD-2022-Sales-presentation\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=vhm4CfeqoqewinjqORzAzr0JqXR9faR4E4m64k8B9U2FlqE0OQWTGl_wbJuxyz4YeeQaU8yDl2f6ew1YAWUfGznBhgY6toxRvWeFZDqxTFtaUupuiESU_SzJQMyBAr77H3UzsRITXvyb45JPdvozFuwsZrV71sn7cU6YJU9MkCr_BYAI2OPFYxmK8M8cH-dG\" target=\"_blank\" rel=\"nofollow noopener\">YTD-2022-Sales-presentation<\/a><\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/OGI5NjYwYjUtNWJjYi00MjI2LWE1MWEtZmU3MjY1ZmMwOTYyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" alt=\"\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"template":"","categories":[3556,3557,6364],"tags":[],"class_list":["post-26396","press_release","type-press_release","status-publish","has-post-thumbnail","hentry","category-corporate-pressrelease-fr","category-financial-pressrelease-fr","category-regulated-info-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen enregistre une forte croissance des ventes au cours des neuf premiers mois de 2022 et confirme ses objectifs financiers pour 2022 - Global<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen enregistre une forte croissance des ventes au cours des neuf premiers mois de 2022 et confirme ses objectifs financiers pour 2022 - Global\" \/>\n<meta property=\"og:url\" content=\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-26T11:58:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1082\" \/>\n\t<meta property=\"og:image:height\" content=\"620\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/\",\"name\":\"Ipsen enregistre une forte croissance des ventes au cours des neuf premiers mois de 2022 et confirme ses objectifs financiers pour 2022 - Global\",\"isPartOf\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg\",\"datePublished\":\"2022-10-27T09:00:00+00:00\",\"dateModified\":\"2023-05-26T11:58:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg\",\"width\":1082,\"height\":620},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/accueil\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen enregistre une forte croissance des ventes au cours des neuf premiers mois de 2022 et confirme ses objectifs financiers pour 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen enregistre une forte croissance des ventes au cours des neuf premiers mois de 2022 et confirme ses objectifs financiers pour 2022 - Global","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Ipsen enregistre une forte croissance des ventes au cours des neuf premiers mois de 2022 et confirme ses objectifs financiers pour 2022 - Global","og_url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/","og_site_name":"Global","article_modified_time":"2023-05-26T11:58:10+00:00","og_image":[{"width":1082,"height":620,"url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/","name":"Ipsen enregistre une forte croissance des ventes au cours des neuf premiers mois de 2022 et confirme ses objectifs financiers pour 2022 - Global","isPartOf":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/#primaryimage"},"image":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg","datePublished":"2022-10-27T09:00:00+00:00","dateModified":"2023-05-26T11:58:10+00:00","breadcrumb":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/#primaryimage","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg","width":1082,"height":620},{"@type":"BreadcrumbList","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-strong-sales-growth-in-the-first-nine-months-of-2022-and-confirms-its-full-year-guidance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/accueil\/"},{"@type":"ListItem","position":2,"name":"Ipsen enregistre une forte croissance des ventes au cours des neuf premiers mois de 2022 et confirme ses objectifs financiers pour 2022"}]},{"@type":"WebSite","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization","name":"IPSEN","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"_links":{"self":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release\/26396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/users\/2"}],"version-history":[{"count":0,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release\/26396\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/media\/27874"}],"wp:attachment":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/media?parent=26396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/categories?post=26396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/tags?post=26396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}